{"product_id":"ktta-vrio-analysis","title":"Pasithea Therapeutics Corp. (KTTA): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Pasithea Therapeutics Corp. (KTTA)'s enduring success with this concise VRIO analysis. We distill whether their key resources are truly Valuable, Rare, Inimitable, and Organized enough to secure a sustainable competitive advantage in the market. Read on below to see the definitive assessment of their strategic capabilities.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 1. PAS-004 Lead Drug Candidate (Macrocyclic MEK Inhibitor)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a promising asset, PAS-004, in a hot market, but the company’s current financial footing adds a layer of complexity to its strategic value. The immediate takeaway is that PAS-004 shows strong early clinical validation against established resistance mechanisms, but its long-term advantage hinges entirely on successful progression through later-stage trials.\u003c\/p\u003e\n\n\u003cp\u003eThe MEK Inhibitor Market itself is expanding rapidly, projected to grow from an estimated USD 6.8 Billion in 2025 to USD 14.9 Billion by 2035, growing at a 9.0% CAGR. This context makes any novel, next-generation candidate like PAS-004 inherently interesting.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Clinical Activity and Pharmacological Profile\u003c\/h3\u003e\n\u003cp\u003ePAS-004 offers value by targeting resistance and toxicity seen with older MEK inhibitors through its novel macrocyclic structure. In the ongoing Phase 1 trial for advanced solid tumors, the drug demonstrated a disease control rate of 71.4% among patients with BRAF-mutated tumors. Furthermore, its pharmacodynamic profile is encouraging: it achieved phosphorylated ERK (pERK) inhibition of approximately 80% near maximum concentration (Cmax) and maintained inhibition above 60% at minimum concentration (Cmin).\u003c\/p\u003e\n\u003cp\u003eThe tablet formulation also shows superior characteristics. The 8mg tablet achieved an AUC of 2,290 ng·h\/mL, which is slightly greater than the 22mg capsule, while maintaining a favorable Cmax\/Cmin ratio below 2. This suggests better predictability and potentially lower dosing requirements for patients.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Next-Generation Mechanism\u003c\/h3\u003e\n\u003cp\u003eA next-generation macrocyclic oral MEK inhibitor is relatively rare in the current treatment paradigm, which is dominated by older generations or non-oral options. While competitors like those developing Binimetinib, Cobimetinib, and Selumetinib are active, PAS-004’s specific structural class represents a less common approach. The company is also exploring broader applications, evidenced by an ALS Association grant to study PAS-004 in ALS patients.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Molecular Complexity\u003c\/h3\u003e\n\u003cp\u003eThe specific molecular architecture and the resulting pharmacokinetic profile of PAS-004 are difficult and time-consuming for competitors to replicate exactly. This inherent complexity in the molecule itself creates a barrier to immediate imitation. The successful development of the tablet formulation, which showed linear PK and dose-proportionality, further solidifies the technical hurdle for rivals attempting to reverse-engineer this specific asset.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Capital and Structure\u003c\/h3\u003e\n\u003cp\u003ePasithea Therapeutics Corp. is organized to advance this asset, evidenced by ongoing Phase 1\/1b trials in both cancer and NF1 patients. Organizationally, the company recently secured a significant capital infusion; they announced a public offering that raised approximately $60 million in gross proceeds, closing on December 1, 2025, which is expected to fund operations through at least the first half of 2028. However, the firm’s operational efficiency is a concern, with a Return on Equity (ROE) around -89.9% and a Return on Assets (ROA) near -83.64%. The CEO’s base salary was recently adjusted to $533,000. The balance sheet shows strong liquidity with a Current Ratio of 4.02 and zero debt.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Scoring\u003c\/h3\u003e\n\u003cp\u003eThe current competitive advantage is best classified as \u003cstrong\u003eTemporary\u003c\/strong\u003e. The positive Phase 1 data, including the recommendation to escalate to Cohort 8 (45mg capsules), provides a strong near-term edge. However, this advantage is contingent on successful validation in larger, later-stage trials and eventual regulatory approval. If those milestones are hit, the advantage could become sustained.\u003c\/p\u003e\n\u003cp\u003eHere is a quick summary of the VRIO assessment for PAS-004:\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data\/Observation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e71.4% DCR in BRAF-mutated tumors; pERK inhibition \u0026gt; 60% at Cmin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eNext-generation macrocyclic oral MEK inhibitor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eSpecific molecular structure and PK profile are hard to replicate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSecured $60M capital infusion; High efficiency deficit (ROE approx. -90%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eDependent on later-stage clinical validation and FDA approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eIf onboarding for the next trial cohort takes longer than expected, the timeline to solidify this advantage will slip, defintely increasing investor uncertainty.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 2. Extended Intellectual Property Portfolio (Patents to at least 2045)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The invention of a crystalline form extends patent protection for PAS-004 to at least \u003cstrong\u003e2045\u003c\/strong\u003e, securing a long-term revenue stream if the drug succeeds. The original protection was believed to extend to \u003cstrong\u003e2032\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Extending patent life from \u003cstrong\u003e2032\u003c\/strong\u003e to at least \u003cstrong\u003e2045\u003c\/strong\u003e is a rare and highly valuable achievement in biotech.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Sustained. Patents are legally protected; imitation is impossible until expiration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The close work with a top IP law firm, \u003cstrong\u003eJones Day\u003c\/strong\u003e, shows a deliberate strategy to maximize asset life. The Company also recently priced a \u003cstrong\u003e$60 million\u003c\/strong\u003e public offering to support ongoing clinical trials, including the Phase 1 trial utilizing the new crystalline substance.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This is a legally defensible, long-term barrier to entry for competitors targeting this specific molecule.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Metric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eReference Year\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOriginal Patent Protection Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2032\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-Crystalline Form\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExtended Patent Protection Estimate\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e2045\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePost-Crystalline Form Filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Legal Counsel\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJones Day\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJanuary 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntangible Assets (Patents and IP Net)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5,687,239\u003c\/strong\u003e thousand\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing to Support Trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePAS-004 is currently being evaluated in a Phase 1 dose escalation trial in advanced cancer patients.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe new crystalline form of PAS-004 is captured in polymorph and stereoisomer patent filings.\u003c\/li\u003e\n\u003cli\u003eThe upcoming Phase 1 dose escalation trial will utilize the newly invented crystalline drug substance.\u003c\/li\u003e\n\u003cli\u003eThe extension of patent life adds approximately \u003cstrong\u003e13 years\u003c\/strong\u003e of potential exclusivity beyond the previous estimate.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 3. Proprietary Drug Discovery Engine (Computational Biology Integration)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This platform allows for the efficient identification and generation of novel therapeutic molecules, reducing early-stage discovery risk and cost.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs claim AI\/computational platforms, but the proven ability to generate a clinical candidate like PAS-004 suggests a functional, rare implementation.\u003c\/p\u003e\n\u003cp\u003eThe tangible output supporting this claim is the progression of PAS-004, a next-generation macrocyclic MEK inhibitor, through human clinical trials, evidenced by specific pharmacokinetic (PK) and pharmacodynamic (PD) data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eCapsule (Cohort 7 - 37mg)\u003c\/th\u003e\n\u003cth\u003eTablet (8mg Cohort)\u003c\/th\u003e\n\u003cth\u003eSignificance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUC (Area Under Curve)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6,690\u003c\/strong\u003e ngh\/mL\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,290\u003c\/strong\u003e ngh\/mL\u003c\/td\u003e\n\u003ctd\u003eSupports sustained exposure potential.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCmax (Peak Concentration)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e313\u003c\/strong\u003e ng\/mL\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e118\u003c\/strong\u003e ng\/mL\u003c\/td\u003e\n\u003ctd\u003ePeak systemic exposure achieved.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCmin (Trough Concentration)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e260\u003c\/strong\u003e ng\/mL\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e75.4\u003c\/strong\u003e ng\/mL\u003c\/td\u003e\n\u003ctd\u003eExposure at 24 hours post-dose.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCmax\/Cmin Ratio\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;\u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;\u003cstrong\u003e2\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIndicates low variability, supporting chronic dosing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003epERK Inhibition (at Cmin)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;\u003cstrong\u003e60%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003ePharmacodynamic evidence of continuous pathway suppression.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. The specific algorithms, data sets, and integration methods are proprietary and hard to reverse-engineer.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. It enabled the creation of PAS-004, but its full exploitation across the pipeline needs further proof.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrailing Twelve Months (TTM) Research \u0026amp; Development (R\u0026amp;D) spend was reported at \u003cstrong\u003e$6.97\u003c\/strong\u003e million as of November 2025.\u003c\/li\u003e\n\u003cli\u003eThe company reported approximately \u003cstrong\u003e$4.1\u003c\/strong\u003e million in Cash \u0026amp; Equivalents as of Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe Debt-to-Equity Ratio is \u003cstrong\u003e0\u003c\/strong\u003e, indicating no debt obligations to manage the pipeline.\u003c\/li\u003e\n\u003cli\u003eReported Revenue for the fiscal year 2022 was \u003cstrong\u003e$486,559\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. It’s a capability that needs continuous investment to maintain its edge over rapidly evolving computational tools.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 4. Positive Early-Stage Clinical Data (Phase 1\/1b Results)\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Interim Phase 1 Data\u003c\/h\u003e\n\u003cp\u003eInterim Phase 1 data for PAS-004 in advanced solid tumors demonstrated an initial Disease Control Rate (DCR) of 71.4% in BRAF-mutated tumors (5 of 7 patients). The overall DCR across 21 efficacy-evaluable patients was 42.8%. An unconfirmed monotherapy partial response showed a tumor reduction of –31.9% in one patient. The asset was de-risked by positive safety data, reporting no DLTs (Dose-Limiting Toxicities) or discontinuations through the DLT period.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eResult\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDCR (BRAF-mutated)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e71.4%\u003c\/strong\u003e (5 of 7)\u003c\/td\u003e\n\u003ctd\u003eInterim Phase 1 Cancer Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall DCR\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e21 Efficacy-Evaluable Patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartial Response\u003c\/td\u003e\n\u003ctd\u003eUnconfirmed, \u003cstrong\u003e–31.9%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBRAF V600E Melanoma Patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo DLTs\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eThrough DLT Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePK AUC (30mg capsule)\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e5,480 ng·h\/mL\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCohort 6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-Life\u003c\/td\u003e\n\u003ctd\u003e$\\approx$ \u003cstrong\u003e60 hours\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCapsule Formulation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Specific Efficacy Signals\u003c\/h\u003e\n\u003cp\u003ePositive Phase 1 data is common; however, achieving a 71.4% DCR in the BRAF-mutated subgroup, including an unconfirmed partial response in a patient previously treated with MEK + BRAF combination therapy, represents a rarer signal in this hard-to-treat population.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Past Trial Results\u003c\/h\u003e\n\u003cp\u003eCompetitors cannot imitate the specific historical trial results, such as the 71.4% DCR or the –31.9% tumor reduction achieved by PAS-004.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: Data Utilization and Expansion\u003c\/h\u003e\n\u003cp\u003eThe company is actively leveraging this data to expand indications, evidenced by securing a $1 million grant from the ALS Association to study PAS-004 in ALS.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eALS Phase 1 Study Patient Count: \u003cstrong\u003e12\u003c\/strong\u003e patients.\u003c\/li\u003e\n\u003cli\u003eALS Phase 1 Study Cohorts: \u003cstrong\u003eThree\u003c\/strong\u003e sequential dose cohorts.\u003c\/li\u003e\n\u003cli\u003eALS Study Follow-up Duration: Approximately \u003cstrong\u003e28 weeks\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial strength contextually supports organization, with a reported Current Ratio of 4.02. Research \u0026amp; Development expenses for the TTM period ending September 2025 were $6.75 million.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary Nature\u003c\/h\u003e\n\u003cp\u003eThe advantage is temporary as the asset progresses; for instance, the tablet formulation showed dose-normalized exposures approximately 3-fold higher than the capsule formulation in the NF1-PN trial.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 5. Non-Dilutive Funding\/Grant Success ($1M ALS Association Award)\u003c\/h2\u003e\n\u003cp\u003eThe award is a $1 million Hoffman ALS Clinical Trial Award from the ALS Association to fund a Phase 1 study of PAS-004 in ALS patients.\u003c\/p\u003e\n\n\u003ch5\u003eValue\u003c\/h5\u003e\n\u003cp\u003eThe $1 million grant provides non-dilutive cash for the Phase 1 study, which involves 12 patients across three dose cohorts with approximately 28 weeks of follow-up. The study will assess safety, tolerability, ALSFRS-R changes, and NfL levels. On the day of the announcement, KTTA stock gained 169.69%, adding approximately $6M to the valuation, reaching a $10M market cap.\u003c\/p\u003e\n\n\u003ch5\u003eRarity\u003c\/h5\u003e\n\u003cp\u003eWinning a competitive grant from the ALS Association, the world's leading funder of ALS research, signals strong scientific merit for PAS-004, which targets MAPK and MEK enzymes.\u003c\/p\u003e\n\n\u003ch5\u003eImitability\u003c\/h5\u003e\n\u003cp\u003eCompetitors cannot replicate the award for this specific project, as the $1 million funding is tied to Pasithea's proprietary PAS-004 development pathway.\u003c\/p\u003e\n\n\u003ch5\u003eOrganization\u003c\/h5\u003e\n\u003cp\u003eThe success demonstrates the team's capability in securing funding from major advocacy groups and navigating the Hoffman Clinical Trial Awards Program.\u003c\/p\u003e\n\n\u003ch5\u003eCompetitive Advantage\u003c\/h5\u003e\n\u003cp\u003eThe advantage is Temporary due to the one-time nature of the cash infusion and validation point. The market reaction showed immediate positive impact, with trading volume at 34.8x the daily average.\u003c\/p\u003e\n\n\u003cp\u003eThe financial context surrounding the grant announcement is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrant Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNon-dilutive funding for Phase 1 ALS trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 Patient Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of ALS patients to be enrolled.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Grant Market Cap\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.16 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eValuation prior to the news release.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-News Stock Gain\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e169.69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePercentage increase on the announcement day.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.02\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates robust liquidity position.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates no debt on the balance sheet.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$5.09\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported earnings for the last twelve months.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe clinical trial design elements supported by the grant include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTarget: PAS-004, a next-generation macrocyclic MEK inhibitor.\u003c\/li\u003e\n\u003cli\u003ePreclinical Validation: Promising results in the SOD mouse model.\u003c\/li\u003e\n\u003cli\u003ePrior Clinical Exposure: PAS-004 already in clinic for neurofibromatosis and advanced cancers.\u003c\/li\u003e\n\u003cli\u003eBiomarker Endpoint: Measurement of neurofilament light chain (NfL) levels.\u003c\/li\u003e\n\u003cli\u003eALS Functional Endpoint: Changes in ALS Functional Rating Scale–Revised (ALSFRS-R) scores.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 6. Strong Cash Runway Post-Financing (Through H1 2028)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe late 2025 \\$60 million public offering extends the cash runway through at least the first half of 2028.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$60,000,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$54,900,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffering Price Per Share\/Unit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.75\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares\/Units Offered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e80,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected Cash Runway End\u003c\/td\u003e\n\u003ctd\u003eFirst half of \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSecuring a runway extending through H1 2028 is a significant achievement for a clinical-stage biotech.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMany clinical-stage biotechs struggle with cash availability.\u003c\/li\u003e\n\u003cli\u003eThe company also secured an award of \u003cstrong\u003e\\$1,000,000\u003c\/strong\u003e from the ALS Association.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe specific terms and timing of the financing are unique to the company's situation.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Detail\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlacement Agent Cash Fee\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7.0%\u003c\/strong\u003e (\u003cstrong\u003e\\$4.2 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlacement Agent Warrants Issued\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsider Share Purchase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e400,000\u003c\/strong\u003e shares for \u003cstrong\u003e\\$300,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Market Cap (Prior to full impact)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$8.63M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe management team successfully executed a major financing event when needed.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFinancing led by healthcare-dedicated investors including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron Capital Management.\u003c\/li\u003e\n\u003cli\u003eH.C. Wainwright \u0026amp; Co. acted as exclusive placement agent.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nTemporary. This advantage is only sustained as long as the cash lasts and is spent effectively on R\u0026amp;D.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet proceeds intended for ongoing research, pre-clinical studies, and clinical trials for PAS-004.\u003c\/li\u003e\n\u003cli\u003eNet proceeds intended for technology development, licensing, and potential acquisitions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 7. Targeted Disease Focus (RASopathies\/MAPK Pathway Expertise)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Deep focus on the MAPK pathway allows for specialized knowledge application, which is critical for designing effective inhibitors and navigating regulatory pathways for these specific diseases.\u003c\/p\u003e\n\u003cp\u003eThe lead candidate, PAS-004, is a next-generation macrocyclic oral MEK 1 and 2 inhibitor intended for RASopathies and MAPK pathway-driven tumors. Preliminary data from the Phase 1 trial in advanced cancer patients showed pERK inhibition of up to \u003cstrong\u003e91%\u003c\/strong\u003e in cohort 3 (\u003cstrong\u003e8mg\u003c\/strong\u003e capsule) and an estimated half-life in excess of \u003cstrong\u003e60 hours\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many target this pathway, a dedicated focus on the nuances of RASopathies and related tumors is a specialized niche.\u003c\/p\u003e\n\u003cp\u003eNeurofibromatosis type 1 (NF1), a RASopathy, affects approximately \u003cstrong\u003e1 in 3,000\u003c\/strong\u003e births. PAS-004 aims to provide a novel therapeutic option beyond AstraZeneca’s Koselugo (selumetinib), which is the only FDA-approved MEK inhibitor for \u003cem\u003epaediatric\u003c\/em\u003e NF1 PN.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Deep institutional knowledge and tacit understanding built over years are hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003eThe development of PAS-004 as a macrocyclic compound suggests a potentially significant advancement in MEK inhibitor selectivity and sustained pathway suppression.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The team’s structure is aligned around this therapeutic area.\u003c\/p\u003e\n\u003cp\u003eThe organization secured a $60 million public offering, extending its cash runway through at least the first half of \u003cstrong\u003e2028\u003c\/strong\u003e to support ongoing research, pre-clinical studies, and clinical trials for PAS-004.\u003c\/p\u003e\n\u003cp\u003eThe Research and Development expense for the nine months ended September 30, 2024, was \u003cstrong\u003e$5,688,478\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Specialized knowledge in a complex biological pathway builds a long-term, hard-to-replicate organizational capability.\u003c\/p\u003e\n\u003cp\u003eAnalyst coverage initiated with a Buy rating and a price target of \u003cstrong\u003e$3.00 USD\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe focus on RASopathies and MAPK pathway-driven tumors is supported by ongoing clinical evaluation:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial\/Indication\u003c\/td\u003e\n\u003ctd\u003eStatus\/Dose Levels\u003c\/td\u003e\n\u003ctd\u003eEnrollment\/Data Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1 (Advanced Cancer)\u003c\/td\u003e\n\u003ctd\u003eDose escalation ongoing; Cohorts up to \u003cstrong\u003e37mg\u003c\/strong\u003e capsules\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21\u003c\/strong\u003e patients enrolled as of April 2, 2025; No DLTs reported.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 1\/1b (NF1-PN Adults)\u003c\/td\u003e\n\u003ctd\u003ePart A planned doses: \u003cstrong\u003e4mg, 8mg, 12mg, 18mg\u003c\/strong\u003e tablets\u003c\/td\u003e\n\u003ctd\u003ePart A to identify RPBD for potential progression to Part B.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company also received a \u003cstrong\u003e$1 million\u003c\/strong\u003e award from the ALS Association to study PAS-004 in amyotrophic lateral sclerosis (ALS).\u003c\/p\u003e\n\u003cp\u003eKey pipeline focus areas include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePAS-004 for Neurofibromatosis Type 1 (NF1-PN).\u003c\/li\u003e\n\u003cli\u003ePAS-004 for MAPK pathway-driven tumors (e.g., BRAFv600 and BRAF fusion tumors).\u003c\/li\u003e\n\u003cli\u003ePAS-004 for Amyotrophic Lateral Sclerosis (ALS).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 8. Experienced Management and R\u0026amp;D Team\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The team has experience in biotechnology innovation, clinical development, and commercialization, which is vital for navigating the complex drug development process.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Experience is common, but having the right mix of regulatory, clinical, and scientific expertise is less so.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Key personnel and their established working relationships are not easily poached or replicated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The team structure supports R\u0026amp;D operations in the Pacific Northwest.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Human capital, especially in specialized science, is a classic source of sustained advantage.\u003c\/p\u003e\n\n\u003cp\u003eThe executive structure and associated compensation reflect the specialized nature of the clinical-stage biotechnology focus.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eExecutive Role\u003c\/td\u003e\n\u003ctd\u003eAnnual Compensation (USD)\u003c\/td\u003e\n\u003ctd\u003eAverage Tenure (Years)\u003c\/td\u003e\n\u003ctd\u003eKey Activity\/Expertise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCEO \u0026amp; Director (Tiago Marques)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$640,059\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical Fellow at Imperial College London\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCFO (Daniel Schneiderman)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$430.22K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eFiscal leadership and strategic financial planning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-Founder, Executive Chairman (Lawrence Steinman)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$297.20K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAdvisory on clinical and commercial development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndependent Director (Alfred Novak)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$91.46K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBoard oversight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific financial and structural data points related to the organization supporting the team's operations include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Employees (FY): \u003cstrong\u003e4\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHeadquarters Location: Miami Beach, Florida\u003c\/li\u003e\n\u003cli\u003eShares of Common Stock Outstanding (as of November 11, 2024): \u003cstrong\u003e1,266,427\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash \u0026amp; Equivalents (Q3 2025): approximately \u003cstrong\u003e$4.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDebt-to-Equity Ratio: \u003cstrong\u003e0\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCompensation details for key scientific advisory roles further illustrate the investment in specialized expertise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProfessor Lawrence Steinman receives \u003cstrong\u003e$25,000 per quarter\u003c\/strong\u003e for consulting and advisory services.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003ePasithea Therapeutics Corp. (KTTA) - VRIO Analysis: 9. Potential Market Size\/Indication Breadth ($20B potential market access)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePotential market across multiple indications where the RAS\/MAPK pathway is mutated estimated at \u003cstrong\u003e$20 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eMEK inhibitor market context (2023):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTAFINLAR+MEKINIST combination net sales: \u003cstrong\u003e~$1.9B\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOther MEK inhibitors (MEKTOVI, KOSELUGO, COTELLIC) net sales: \u003cstrong\u003e~$500M\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePotential is high; addressable market depends on clinical success in indications including NF1-PN, solid tumors, and ALS.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePath to market via PAS-004 is unique.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrganizational intent shown by pursuing multiple indications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1 trial dosing for NF1-PN expected to be completed by \u003cstrong\u003eQ1 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRevenue Growth (Dec 2024): \u003cstrong\u003e0%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRolling three-period average Revenue Growth: \u003cstrong\u003e1,010.1%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; becomes sustained upon successful indication expansion.\u003c\/p\u003e\n\u003cp\u003eVRIO Analysis Summary for Potential Market Size\/Indication Breadth\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20 billion\u003c\/strong\u003e potential market access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eDependent on clinical success across indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eUnique path via PAS-004\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003ePursuing NF1-PN, Solid Tumors, ALS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial Context: Capital Raise and Runway Extension\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Date\u003c\/td\u003e\n\u003ctd\u003eSource\/Detail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Proceeds from Offering\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$60 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePublic Offering closed December 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds (Approximate)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAfter placement agent fees and expenses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Runway Extended Through\u003c\/td\u003e\n\u003ctd\u003eFirst half of \u003cstrong\u003e2028\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFunding for ongoing research and clinical trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOffering Price Per Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.75\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e80,000,000 shares\/pre-funded warrants offered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: Q4 2025 Cash Burn Projection Context\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003e$60 million\u003c\/strong\u003e raise, resulting in approximately \u003cstrong\u003e$54.9 million\u003c\/strong\u003e net proceeds, is projected to sustain operations through at least the first half of \u003cstrong\u003e2028\u003c\/strong\u003e.\u003c\/p\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516196446357,"sku":"ktta-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ktta-vrio-analysis.png?v=1740204277","url":"https:\/\/dcf-model.com\/products\/ktta-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}